Skip to main content
Clinical Trials/EUCTR2016-000709-36-GB
EUCTR2016-000709-36-GB
Active, not recruiting
Phase 1

Research into Antipsychotic Discontinuation and Reduction (RADAR): A Randomised Controlled Trial - RADAR Trial

C0 sites402 target enrollmentMay 23, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Schizophrenia, delusional disorders, schizoaffective disorder, psychosis
Sponsor
C
Enrollment
402
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 23, 2018
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
C

Eligibility Criteria

Inclusion Criteria

  • 1\.Aged over 18 years
  • 2\.A clinical and/or ICD10 diagnosis of schizophrenia, schizoaffective disorder, delusional disorder or other non\-affective psychosis
  • 3\.More than one previous episode of relapse or psychotic exacerbation, or a single episode lasting more than one year
  • 4\.Taking antipsychotic medication
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 302
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 100

Exclusion Criteria

  • 1\.Participant lacks capacity to consent to the trial
  • 2\.Participant has insufficient command of spoken English to understand trial procedures
  • 3\.Participant subject to a Community Treatment Order (CTO) that includes a requirement to take antipsychotic medication
  • 4\.Clinician considers there will be a serious risk of harm to self or others
  • 5\.Participant has been admitted to hospital or had treatment from the Home Treatment or Crisis Team within the last month
  • 6\.Females who have a confirmed pregnancy
  • 7\.Females who are breast\-feeding
  • 8\.Involvement in another IMP trial
  • 9\.No contraindications to continuing on antipsychotic medication

Outcomes

Primary Outcomes

Not specified

Similar Trials